(Q33163717)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

myelodysplastic syndrome

1 reference

inferred from title

acute myeloid leukemia

1 reference

inferred from title

author

Sridurga Mithraprabhu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Peter Mollee

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Anthony E Dear

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

P Tan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

A Wei

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

N Cummings

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

H B Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

M Perugini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

K Reed

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

S Avery

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

S Patil

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

P Walker

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

A Grigg

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

R D'Andrea

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

A Spencer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

10 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

e170

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

5 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

International scoring system for evaluating prognosis in myelodysplastic syndromes

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3913937

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

Methods for the analysis of histone H3 and H4 acetylation in blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBCJ.2013.68

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

21 January 2018

1 reference

12 December 2020

Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome

1 reference

12 December 2020

Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia

1 reference

12 December 2020

Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program

1 reference

12 December 2020

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

12 December 2020

Identifiers

DOI

10.1038/BCJ.2013.68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

5 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

PubMed publication ID

24413064

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24413064%20AND%20SRC:MED&resulttype=core&format=json